$-0.13 EPS Expected for Arrowhead Pharmaceuticals, Inc. (ARWR)

December 8, 2017 - By Marie Mckinney

 $ 0.13 EPS Expected for Arrowhead Pharmaceuticals, Inc. (ARWR)

Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.13 EPS on December, 13.They anticipate $0.18 EPS change or 58.06 % from last quarter’s $-0.31 EPS. After having $-0.07 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see 85.71 % EPS growth. The stock increased 4.05% or $0.14 during the last trading session, reaching $3.6. About 1.77M shares traded or 64.28% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since December 8, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Arrowhead Research Corp has $20.0 highest and $2.0 lowest target. $2.88’s average target is -20.00% below currents $3.6 stock price. Arrowhead Research Corp had 18 analyst reports since August 5, 2015 according to SRatingsIntel. Chardan Capital Markets downgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Wednesday, November 30 to “Neutral” rating. The rating was maintained by Chardan Capital Markets on Thursday, November 10 with “Buy”. The company was maintained on Thursday, September 14 by Piper Jaffray. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Hold” rating given on Wednesday, November 30 by Cantor Fitzgerald. Jefferies maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Monday, June 26. Jefferies has “Hold” rating and $200 target. The firm has “Mkt Perform” rating by William Blair given on Wednesday, November 30. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Monday, September 25 with “Hold” rating. The stock has “Outperform” rating by William Blair on Monday, September 18. As per Friday, September 25, the company rating was maintained by Piper Jaffray. Chardan Capital Markets initiated it with “Buy” rating and $12 target in Thursday, May 19 report.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $269.18 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

More important recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Businesswire.com which released: “Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results” on December 05, 2017, also Businesswire.com published article titled: “Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver …”, Businesswire.com published: “Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response …” on December 06, 2017. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was released by: Fool.com and their article: “Here’s What Caused Arrowhead Pharmaceuticals’ Stock to Spike Today” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.